LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China

The article states that China has an anti-amyloid Alzheimer’s therapy that is the first of its kind in the country and enables at-home administration. No efficacy, pricing, approvals timeline, or financial details are provided, limiting the ability to gauge near-term market impact.